Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

, and a sense of an impending attack was the most reliable prodrome, according to new US Hereditary Angioedema Association (US HAEA) Scientific Registry data.¹

The analysis examined trigger and prodrome types, frequency, and their relationship to attack onset.¹ Data came from 2 cohorts: patients with HAE due to C1 inhibitor deficiency (HAE-C1INH) and patients with angioedema non-mast cell-mediated with normal C1 inhibitor (ANM-nl-C1INH).¹ Prospective prodrome data have been limited; in 1 prior survey of 21 patients reporting on 253 treated attacks, prodromes preceded 67.6% (171/253) of attacks, with a median lead time of 12 hours.²

"Our analysis highlighted the importance of stress and hormonal attack triggers," wrote Sandra C. Christiansen, MD, of the Department of Medicine at the University of California San Diego, and colleagues.

Hereditary Angioedema Triggers and Prodromes in HAE-C1INH

Of 485 participants in the HAE-C1INH cohort, 458 recorded ≥ 1 trigger.¹ Stress was the most frequently reported trigger (91.5%), followed by minor trauma (83.2%) and infection (67.3%).¹ Hormonal triggers were the most likely to always be followed by an attack.¹

Prodromal symptoms were reported by 399 of 485 participants (82.3%).¹ The most frequent prodrome was a non-itchy rash (78.7%), followed by a sense or hunch of an impending attack (52.6%), tiredness or fatigue (47.2%), and a tightness or prickling sensation (45.8%).¹

Although less common than rash, the sense or hunch carried the strongest link to a subsequent attack. It was the prodrome most likely to always be followed by an attack (47.4%).¹ Erythema marginatum-type eruptions were common across all participants, according to the investigators.¹

Triggers and Prodromes in Angioedema With Normal C1 Inhibitor

Stress was the most common attack trigger in both the HAE-C1INH (91.5%) and ANM-nl-C1INH (81.25%) cohorts of the US HAEA Scientific Registry.

Hormonal triggers in HAE-C1INH and menses in ANM-nl-C1INH were the triggers most likely to always be followed by an attack.

A sense or hunch of an impending attack was the most reliable prodrome in HAE-C1INH (47.4%), versus tightness or prickling in ANM-nl-C1INH (62.2%).

In the ANM-nl-C1INH cohort, 83 of 96 participants documented ≥ 1 trigger.¹ Stress was again the most common trigger (81.25%), and menses was the trigger most likely to always be followed by an attack (38.5%).¹

Prodromal symptoms were reported by 83 of 96 participants.¹ Tightness or prickling was the most common prodrome (58.3%), followed by tiredness or fatigue (56.3%), non-itchy rash (51.0%), and a sense or hunch of an impending attack (45.8%).¹

In contrast with the HAE-C1INH cohort, the most reliable prodrome in this group was a tightness or prickling sensation, which had the greatest likelihood of always being followed by an attack (62.2%).¹ Across both cohorts, stress led all reported triggers, and hormonal factors showed the strongest association with subsequent attacks.¹

The findings extend prior work suggesting prodromes often occur early enough to allow on-demand treatment to begin before swelling develops.² The registry data point to a patient-reported sense of an impending attack in HAE-C1INH, and tightness or prickling in ANM-nl-C1INH as the prodromes most consistently tied to attack onset.¹

“We hypothesize that triggers and prodromes are fundamentally interconnected with attacks of HAE through activation of kinin generating pathways,” investigators concluded.

Christiansen SC, Wilmot J, Selva C, et al. The US HAEA Scientific Registry: triggers and prodromes. 

Prematta MJ, Bewtra AK, Levy RJ, et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. 

Articles

Registry-derived patient-reported data from HAE-C1INH and non–mast cell-mediated angioedema with normal C1 inhibitor cohorts identify stress as the dominant trigger, with hormonal factors most consistently followed by attacks. Prodromes were frequent in both populations and appeared to precede swelling with clinically actionable lead time. In HAE-C1INH, erythema marginatum–type rash was most common, but a subjective “hunch” of an impending attack best predicted attack onset. In ANM-nl-C1INH, tightness/prickling was both common and most predictive.

Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Hereditary Angioedema Triggers, Prodromes Mapped in US HAEA Registry

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals. Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine.

 Priority Review of Insmed's supplemental new drug application (sNDA) for amikacin liposome inhalation suspension (Arikayce) for Mycobacterium avium complex (MAC) lung disease, the approval of a sotatercept-csrk (Winrevair) label update to include efficacy and safety data from the phase 3 HYPERION trial in adults with pulmonary arterial hypertension (PAH) diagnosed within the previous 12 months, phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 data for barzolvolimab in antihistamine-refractory 

, and the FDA approvals of insulin efsitora alfa-gobe (Onswik) to improve glycemic control in adults with 

 as well as obinutuzumab (Gazyva) for adult and pediatric patients ≥ 2 years of age with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of September 20, 2026 — let's jump in!

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

On September 21, 2026, the FDA granted Priority Review to Insmed's supplemental new drug application (sNDA) for amikacin liposome inhalation suspension (ALIS; Arikayce) seeking full approval for newly diagnosed and recurrently infected MAC lung disease.

Amikacin liposome inhalation suspension is currently approved only under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for refractory MAC lung disease in patients who have failed ≥ 6 months of multidrug therapy without achieving negative sputum culture conversion. If approved, the sNDA would expand the label to frontline use as part of combination antibacterial therapy, moving amikacin liposome inhalation suspension from a refractory-disease option to a treatment-naive one.

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

On September 22, 2026, the FDA approved a label update for sotatercept-csrk (Winrevair) to include efficacy and safety data from the phase 3 HYPERION trial in adults with PAH diagnosed within the previous 12 months.

The activin signaling inhibitor already carries approval for adults with PAH (WHO Group 1) to improve exercise capacity and WHO functional class and to reduce clinical worsening events, including hospitalization, lung transplantation, and death. The HYPERION update extends label evidence to patients earlier in their disease course, adding to prior data from the STELLAR and ZENITH trials.

EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials

On September 22, 2026, Celldex Therapeutics reported topline results from the phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab (CDX-0159), showing the anti-KIT monoclonal antibody met the primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at week 12 in patients with antihistamine-refractory CSU. The studies represent the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU.

Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes

On September 24, 2026, the FDA approved insulin efsitora alfa-gobe (Onswik), a once-weekly basal insulin, to improve glycemic control in adults with type 2 diabetes, based on 4 phase 3 QWINT trials. According to parent company Eli Lilly, efsitora is designed to maintain steady basal insulin levels across a full 7-day dosing interval, reducing basal injections from approximately 365 to 52 per year vs once-daily basal insulin. The US decision is the fourth global approval for efsitora in type 2 diabetes, following actions in the European Union, Mexico, and Japan.

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

On September 25, 2026, the FDA approved obinutuzumab (Gazyva) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission. The decision makes obinutuzumab the first FDA-approved treatment option for idiopathic nephrotic syndrome in 70 years and was supported by data from the phase 3 INShore study showing a greater proportion of people experienced no relapses after week 8 and were in complete remission at one year with obinutuzumab (95%) compared with mycophenolate mofetil (73%).

Five late-September 2026 regulatory and late-stage clinical updates span infectious disease, PAH, immunology, diabetes, and nephrology. The FDA granted Priority Review for an Arikayce sNDA that could move inhaled liposomal amikacin into frontline combination therapy for newly diagnosed or recurrent MAC lung disease. Sotatercept’s label now incorporates phase 3 HYPERION data in adults with PAH diagnosed within 12 months. Barzolvolimab met week-12 UAS7 endpoints in two phase 3 CSU trials. FDA approvals also include once-weekly insulin efsitora for type 2 diabetes and obinutuzumab to prevent relapse in frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome.

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 has approved Eli Lilly and Company's Olumiant (baricitinib) for patients ages 12 and older with severe alopecia areata, the company announced September 25. The approval expands the oral medication's US indication to include adolescents.

Alopecia areata is a chronic immune-mediated disease that causes unpredictable hair loss. Up to 2% of people develop alopecia areata during their lifetime, and nearly 40% of cases begin before age 20. Disease onset during childhood or adolescence can be associated with more extensive hair loss.

Baricitinib Trial Shows Hair Regrowth in Adolescents With Alopecia Areata

The approval was supported by 36-week results from the adolescent group in 

, a Phase 3 study evaluating baricitinib in pediatric patients with severe alopecia areata. Participants were ages 12 to 17 years. The median baseline Severity of Alopecia Tool (SALT) score was 100, indicating complete scalp hair loss, and the mean duration of the current episode of severe alopecia areata was 6.4 years.

At week 36, 42% of patients receiving baricitinib 4 mg and 27% receiving 2 mg achieved a SALT score of 20 or less, corresponding to at least 80% scalp hair coverage, compared with 5% of patients receiving placebo. For a SALT score of 10 or less, corresponding to at least 90% scalp hair coverage, the rates were 37% with 4 mg and 21% with 2 mg, compared with 2% with placebo.

Patients receiving baricitinib 4 mg who entered the study with substantial eyebrow and eyelash hair loss also had improvements in those areas.

"Severe alopecia areata that starts early in life can be more extensive and harder to treat over time, making it important to consider all available treatment options early in the course of disease," said Brittany Craiglow, MD, adjunct associate professor of dermatology, Yale School of Medicine. "The evidence supporting Olumiant's approval is particularly meaningful because it comes from a Phase 3 study specifically designed for pediatric patients, helping clinicians and families make more informed decisions when considering advanced therapies."

Baricitinib Safety and Dosing for Adolescent Alopecia Areata

Lilly reported that the safety profile observed in adolescents was consistent with that reported in adults with severe alopecia areata.

Olumiant carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The prescribing information also includes warnings and precautions related to hypersensitivity, gastrointestinal perforations, laboratory abnormalities, and vaccinations.

For severe alopecia areata, the recommended dose is 2 mg once daily, with an increase to 4 mg once daily if the response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, treatment with 4 mg once daily may be considered. The dose should be reduced to 2 mg once daily after an adequate response is achieved.

FDA Approval of Baricitinib for Alopecia Areata in Adolescents

Olumiant is a once-daily oral JAK inhibitor discovered by Incyte and licensed to Lilly. In 2022, the FDA approved baricitinib for adults with severe alopecia areata. The drug is also approved in the United States for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to 1 or more tumor necrosis factor blockers and for hospitalized adults with COVID-19 requiring supplemental oxygen or more advanced respiratory support.

The European Commission approved baricitinib for adolescents ages 12 and older with severe alopecia areata in April 2026.

Lilly reported that more than 33,000 patients in the United States had been prescribed Olumiant since 2017. The figure encompasses the drug's US indications and is not specific to alopecia areata.

FDA expanded baricitinib’s US indication to treat severe alopecia areata in patients aged ≥12 years, addressing a chronic immune-mediated condition with frequent onset before age 20 and potentially more extensive disease when early. Approval is supported by 36-week Phase 3 BRAVE-AA-PEDS data in adolescents with profound baseline scalp hair loss (median SALT 100; mean episode duration 6.4 years), demonstrating dose-dependent scalp hair regrowth versus placebo and improvements in eyebrows/eyelashes. Safety in adolescents aligned with adult experience, with existing boxed warnings.

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

FDA News

Alopecia

FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

The US Food and Drug Administration (FDA)

 has approved zilurgisertib (Atebrioz) tablets to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).

The FDA approved zilurgisertib (Atebrioz), an oral ALK2 inhibitor, for FOP in patients aged 12 years and older, making it the third approved FOP therapy.

In PROGRESS, total new HO volume fell by a mean of 3.2 cm³ with zilurgisertib vs a 24.6 cm³ increase with placebo at week 24.

The prespecified primary endpoint, proportion of patients with new HO lesions, showed an 81% relative reduction but did not reach statistical significance (P = .0986).

No AEs led to discontinuation or dose reduction; the label warns of embryo-fetal toxicity.

Pediatric cohorts down to age 2 years are ongoing.

The approval, announced September 25, 2026, is based on the randomized, double-blind, placebo-controlled phase 2 PROGRESS trial. The recommended starting dosage is 100 mg orally once daily, with or without food.

Zilurgisertib, an oral small-molecule activin receptor-like kinase 2 (ALK2) inhibitor developed by Mirum Pharmaceuticals under license from Incyte, is the third FDA-approved therapy for FOP. It follows the 2023 approval of palovarotene (Sohonos), an oral retinoic acid receptor gamma agonist, and the August 2026 approval of garetosmab-grts (Pasatru), an intravenous activin A antibody dosed every 4 weeks. Unlike garetosmab, whose label is limited to adults, zilurgisertib is indicated for patients as young as 12 years.

Cohort 1 of PROGRESS randomized 63 patients aged 12 years and older 1:1 to zilurgisertib 100 mg (n = 32) or placebo (n = 31) once daily for 24 weeks. A single-arm, open-label extension followed, during which all patients received zilurgisertib 100 mg daily. Mean age at baseline was approximately 21 years, and treatment groups were generally balanced, according to Mirum and Incyte.

The FDA based its efficacy assessment on change from baseline in the volume of total new HO vs placebo during the double-blind period, measured by whole-body CT. At week 24, patients receiving zilurgisertib had a mean decrease of 3.2 cm

, compared with a mean increase of 24.6 cm

 in the placebo group (nominal P = .004).

The prespecified primary endpoint of PROGRESS was the proportion of patients developing new HO lesions at week 24. One patient (3.1%) in the zilurgisertib arm developed new lesions vs five patients (16.7%) in the placebo arm, an 81% relative reduction (P = .0986). This difference did not reach statistical significance.

Zilurgisertib secondary outcomes and safety in FOP

Mean volume of new HO lesions at week 24 was 0.003 cm

 with placebo, a reduction exceeding 99% (nominal P < .0001). Annualized new flares averaged 2.34 with zilurgisertib vs 4.55 with placebo.

Through week 48, no new HO lesions were observed among 61 patients with available whole-body CT data, including patients crossing over from placebo at week 24. From week 24 to week 48, total HO lesion volume continued to decline in the continuous zilurgisertib group (mean change, −6.37 cm

) and the crossover group (mean change, −5.32 cm

According to Mirum and Incyte, most adverse events (AEs) during the placebo-controlled period were mild or moderate, and no AEs led to discontinuation or dose reduction. The most common AEs with zilurgisertib were FOP flare-up or FOP-related pain (25%), headache (21.9%), upper respiratory tract infection (21.9%), arthralgia (18.8%), epistaxis (12.5%), and nausea (12.5%). Serious AEs and grade 3 or higher AEs occurred at low rates in both arms.

The label carries a warning for embryo-fetal toxicity based on animal data. Patients of reproductive potential should use effective contraception and discontinue zilurgisertib immediately if pregnancy occurs. The label also restricts coadministration with certain concomitant medications.

Joanne Quan, MD, chief medical officer at Mirum Pharmaceuticals, said at the time of the PROGRESS data release, "People living with FOP and their families urgently need additional treatment options."² The pivotal Cohort 1 results were presented as a late-breaking abstract at ENDO 2026 in June.²

Additional PROGRESS cohorts are evaluating zilurgisertib in children aged 6 to younger than 12 years and in children aged 2 to younger than 12 years. The FDA granted the application fast track, priority review, and orphan drug designations.

US Food and Drug Administration. FDA approves third treatment for fibrodysplasia ossificans progressiva. Published September 25, 2026. Accessed September 25, 2026. 

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva

Mirum Pharmaceuticals, Incyte. Mirum Pharmaceuticals and Incyte announce positive pivotal phase 2 results from PROGRESS study of zilurgisertib in fibrodysplasia ossificans progressiva. Published June 14, 2026. Accessed September 25, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-and-Incyte-Announce-Positive-Pivotal-Phase-2-Results-from-PROGRESS-Study-of-Zilurgisertib-in-Fibrodysplasia-Ossificans-Progressiva/default.aspx

US Food and Drug Administration. FDA approves first treatment for fibrodysplasia ossificans progressiva. Published August 16, 2023. Accessed September 25, 2026. 

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-fibrodysplasia-ossificans-progressiva

US Food and Drug Administration. FDA approves second treatment for fibrodysplasia ossificans progressiva. Published August 19, 2026. Accessed September 25, 2026. 

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva

FDA approval of zilurgisertib (Atebrioz), an oral ALK2 inhibitor, expands the FOP armamentarium as the third available therapy and the first newly approved option down to age 12 since palovarotene. Authorization is supported by phase 2 PROGRESS data showing significant reduction in total new heterotopic ossification volume by whole-body CT at 24 weeks versus placebo, despite a nonsignificant primary endpoint on the proportion developing new lesions. Safety was largely mild-to-moderate, with embryo-fetal toxicity warnings and drug–drug interaction restrictions.

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Once-weekly basal insulin options for adults with 

 have doubled in 2026, with the FDA approval of insulin efsitora alfa-gobe (Onswik) following the March clearance of insulin icodec-abae (Awiqli). Efsitora pairs a fixed weekly regimen with two high-concentration pen formulations built for a wide dosing range.

, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed the September 24, 2026, approval of Eli Lilly's efsitora, its supporting phase 3 evidence, and practical considerations for prescribing.

FDA Approves a Second Once-Weekly Basal Insulin: What the QWINT Data Show

Watch the full episode discussing the FDA’s approval of efsitora alfa-gobe

The approval rests on four phase 3 QWINT trials comparing efsitora with daily insulin glargine U-100 or insulin degludec U-100. Efsitora met the primary endpoint of noninferior A1C reduction in each study, with reductions ranging from 0.81 to 1.26 percentage points. Because insulin trials target comparability rather than superiority, these results support substituting efsitora for daily basal insulin without sacrificing glycemic control.

Hypoglycemia data offer a clearer point of differentiation. Rates of clinically significant or severe hypoglycemia were similar to daily comparators across the program, but insulin-naive participants in QWINT-1 experienced 43% fewer events than those receiving glargine. A flatter steady-state profile may account for the gap, since glargine varies between individuals and may not provide full 24-hour coverage in every patient.

Titration strategy likely contributes as well, and optimal initiation and titration approaches are still being refined, as occurred with icodec. The indication excludes type 1 diabetes, where trials showed higher hypoglycemia rates, although clinicians can envision future use cases in this population.

Dosing logistics differ meaningfully from icodec, a U-700 formulation dosed in 10-unit increments. The efsitora U-500 pen delivers up to 400 units per injection in five-unit increments, while the U-1000 pen delivers up to 800 units in 10-unit increments for patients with higher requirements. Dividing weekly doses by seven gives the daily equivalent, so a 400-unit injection corresponds to roughly 57 units per day.

With two weekly basal insulins now available, clinicians face a new learning curve around pen concentrations, dose increments, and quantities per prescription. Efsitora's hypoglycemia profile in insulin-naive patients may make it an appealing option for basal insulin initiation, where reducing injection burden could help address delays in starting therapy.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Rosenstock J, Bailey T, Connery L, et al. Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. 

Philis-Tsimikas A, Bergenstal RM, Bailey TS, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. 

Blevins T, Dahl D, Pérez Manghi FC, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. 

Videos

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's approval of a new basal insulin for T2D.

Type 2 Diabetes

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

Ari Cohen, MD, MBA, is director of the Transplant Institute at Ochsner Health. 

An Ochsner transplant surgeon discusses 10,000 transplants and how new tools are expanding who can receive an organ. 

Chronic Kidney Disease

Hepatology

Strategic Alliance Partnership

Robotics and Organ Preservation in Transplant, With Ari Cohen, MD, MBA

Sarah Norman, MPP, executive director of BrainFutures.

As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

What The FDA Psychedelic Hearing Means for Psychiatrists 

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss UACR screening for patients with CKD and T1D.

Type 1 Diabetes

UACR Screening and Finerenone Safety in Diabetic CKD

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

A multicenter registry investigator details real-world AFib incidence with mavacamten and compares it against pivotal trial findings.

Video Series

Understanding EXPLORER-HCM and VALOR-HCM AFib Signals

Clinicians weigh how their real-world obstructive HCM patients compare with EXPLORER-HCM and VALOR-HCM trial cohorts.

Comparing Clinical Experience to Trials in oHCM Patients

Killian Lozach, MBA, business development and alliance management lead, Woodberry Associates.

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA

Podcasts

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: Is Becoming a Doctor Still Worth It?

Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.

Latest News

Hereditary Angioedema Triggers, Prodromes Mapped in US HAEA Registry

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata

Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older

FDA Approves a Second Once-Weekly Basal Insulin: What the QWINT Data Show